Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021

Enrique Gea-Izquierdo; Ruth Gil-Prieto; Valentín Hernández-Barrera; Ángel Gil-de-Miguel

doi:10.1080/21645515.2023.2231818

Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021

Enrique Gea-Izquierdo^*
, Ruth Gil-Prieto
, Valentín Hernández-Barrera
, Ángel Gil-de-Miguel

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Respiratory syncytial virus (RSV) is the leading cause of severe respiratory infections in children. In many countries, changes in RSV hospitalizations have occurred during COVID-19 restriction, with alterations in annual pre-pandemic trends. The objective of this retrospective study was to describe the epidemiology of RSV during the pandemic in Spain (2018–2021) through population-based estimates of hospitalization in children <2 years old. A total of 56,741 hospital discharges were identified with a 2.2% decrease between the beginning and the end of the COVID-19 pandemic resulting in a hospitalization rate of 1,915.89 (95% CI = 1,900.13–1,931.65) hospitalizations per 100,000 children. During the four-year period, a total of 34 deaths were recorded (males 63%, females 37%). The average annual cost to the National Health-Care System of bronchiolitis requiring hospitalization was €49,6 million with an average hospitalization cost per case of €3,054. RSV is a very frequent virus associated with community-acquired pneumonia (CAP) in children under 2 years old, so future preventive interventions should target this age group including vaccination programs.

Original language	English
Article number	2231818
Journal	Human Vaccines and Immunotherapeutics
Volume	19
Issue number	2
DOIs	https://doi.org/10.1080/21645515.2023.2231818
State	Published - 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

Funding

Enrique Gea-Izquierdo received a María Zambrano Program fund from the European Union-Spain. This research study is part of the research activities of the “Cathedra in Vaccines Research from Rey Juan Carlos University”, which is sponsored by Sanofi. The authors thank the Subdirección General del Instituto de Información Sanitaria for providing the information on which this study is based.

Funders
European Union-Spain
Instituto de Información Sanitaria
Sanofi
Universidad Rey Juan Carlos

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Bronchiolitis
COVID-19
Spain
epidemiology
respiratory syncytial virus

Access to Document

10.1080/21645515.2023.2231818

Cite this

@article{43cd82bf120c4faf932841e9245060e0,

title = "Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021",

abstract = "Respiratory syncytial virus (RSV) is the leading cause of severe respiratory infections in children. In many countries, changes in RSV hospitalizations have occurred during COVID-19 restriction, with alterations in annual pre-pandemic trends. The objective of this retrospective study was to describe the epidemiology of RSV during the pandemic in Spain (2018{\textendash}2021) through population-based estimates of hospitalization in children <2 years old. A total of 56,741 hospital discharges were identified with a 2.2\% decrease between the beginning and the end of the COVID-19 pandemic resulting in a hospitalization rate of 1,915.89 (95\% CI = 1,900.13{\textendash}1,931.65) hospitalizations per 100,000 children. During the four-year period, a total of 34 deaths were recorded (males 63\%, females 37\%). The average annual cost to the National Health-Care System of bronchiolitis requiring hospitalization was €49,6 million with an average hospitalization cost per case of €3,054. RSV is a very frequent virus associated with community-acquired pneumonia (CAP) in children under 2 years old, so future preventive interventions should target this age group including vaccination programs.",

keywords = "Bronchiolitis, COVID-19, Spain, epidemiology, respiratory syncytial virus",

author = "Enrique Gea-Izquierdo and Ruth Gil-Prieto and Valent{\'i}n Hern{\'a}ndez-Barrera and {\'A}ngel Gil-de-Miguel",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published with license by Taylor \& Francis Group, LLC.",

year = "2023",

doi = "10.1080/21645515.2023.2231818",

language = "English",

volume = "19",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021

AU - Gea-Izquierdo, Enrique

AU - Gil-Prieto, Ruth

AU - Hernández-Barrera, Valentín

AU - Gil-de-Miguel, Ángel

PY - 2023

Y1 - 2023

N2 - Respiratory syncytial virus (RSV) is the leading cause of severe respiratory infections in children. In many countries, changes in RSV hospitalizations have occurred during COVID-19 restriction, with alterations in annual pre-pandemic trends. The objective of this retrospective study was to describe the epidemiology of RSV during the pandemic in Spain (2018–2021) through population-based estimates of hospitalization in children <2 years old. A total of 56,741 hospital discharges were identified with a 2.2% decrease between the beginning and the end of the COVID-19 pandemic resulting in a hospitalization rate of 1,915.89 (95% CI = 1,900.13–1,931.65) hospitalizations per 100,000 children. During the four-year period, a total of 34 deaths were recorded (males 63%, females 37%). The average annual cost to the National Health-Care System of bronchiolitis requiring hospitalization was €49,6 million with an average hospitalization cost per case of €3,054. RSV is a very frequent virus associated with community-acquired pneumonia (CAP) in children under 2 years old, so future preventive interventions should target this age group including vaccination programs.

AB - Respiratory syncytial virus (RSV) is the leading cause of severe respiratory infections in children. In many countries, changes in RSV hospitalizations have occurred during COVID-19 restriction, with alterations in annual pre-pandemic trends. The objective of this retrospective study was to describe the epidemiology of RSV during the pandemic in Spain (2018–2021) through population-based estimates of hospitalization in children <2 years old. A total of 56,741 hospital discharges were identified with a 2.2% decrease between the beginning and the end of the COVID-19 pandemic resulting in a hospitalization rate of 1,915.89 (95% CI = 1,900.13–1,931.65) hospitalizations per 100,000 children. During the four-year period, a total of 34 deaths were recorded (males 63%, females 37%). The average annual cost to the National Health-Care System of bronchiolitis requiring hospitalization was €49,6 million with an average hospitalization cost per case of €3,054. RSV is a very frequent virus associated with community-acquired pneumonia (CAP) in children under 2 years old, so future preventive interventions should target this age group including vaccination programs.

KW - Bronchiolitis

KW - COVID-19

KW - Spain

KW - epidemiology

KW - respiratory syncytial virus

UR - https://www.scopus.com/pages/publications/85164844464

U2 - 10.1080/21645515.2023.2231818

DO - 10.1080/21645515.2023.2231818

M3 - Article

C2 - 37435824

AN - SCOPUS:85164844464

SN - 2164-5515

VL - 19

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

IS - 2

M1 - 2231818

ER -

Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Cite this